YM155 (Survivin suppressor)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for YM155 (Survivin suppressor), covering 2013-04-04 to 2013-04-04. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) [Phase 1, Phase 2]